Monte Rosa Q1 net loss $32M; pipeline advances with MRT-2359, MRT-6160, MRT-8102 milestones

Monte Rosa Therapeutics, Inc.

Q1 2024 net loss $32.0M; cash $197.8M (down from $237.0M Dec 2023), sufficient into H1 2026.
MRT-2359: RP2D determination expected Q2 2024, Phase 1 clinical data H2 2024, Phase 2 before year-end.
MRT-6160: IND submission Q2 2024, Phase 1 SAD/MAD study mid-2024, data Q1 2025; favorable GLP tox profile.
MRT-8102: NEK7-directed MGD shows CNS exposure in NHPs; IND on track for Q1 2025.
New CCNE1-directed MGD discovery program launched for previously undruggable oncology target.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.72

Monte Rosa Therapeutics, Inc. reported financial results for the first quarter ending March 31, 2024.

Period: the first quarter ending March 31, 2024
Result: reported results

Exact text from the filing

Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

View on SEC.gov

1051 earnings releases filed in the last 30 days. Browse all earnings releases →

Monte Rosa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056253

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.